Website beoordeling takeda.com
Takeda Pharmaceuticals: Global Homepage
Gegenereerd op Maart 04 2026 10:15 AM
Oude statistieken? UPDATE !
De score is 53/100
SEO Content
Title
Takeda Pharmaceuticals: Global Homepage
Lengte : 39
Perfect, uw title tag bevat tussen de 10 en 70 karakters.
Description
Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Lengte : 131
Perfect, uw meta description bevat tussen de 70 en 160 karakters.
Keywords
Erg slecht. We hebben geen meta keywords gevonden in uw website. Gebruik deze gratis online meta tags generator om keywords te genereren.
Og Meta Properties
Goed, uw page maakt gebruik van Og Properties.
| Property | Content |
|---|---|
| title | Takeda Pharmaceuticals: Global Homepage |
| description | Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future. |
| url | https://www.takeda.com/ |
| locale | en |
| image | http://assets-dam.takeda.com/image/upload/v1683892920/Global/OG%20Logo.jpg |
| image:secure_url | https://assets-dam.takeda.com/image/upload/v1683892920/Global/OG%20Logo.jpg |
| image:width | 1200 |
| image:height | 627 |
| image:type | image |
| image:alt | Takeda Pharmaceuticals: Global Homepage |
| type | website |
Headings
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 5 | 14 | 0 | 0 | 0 |
- [H1] Takeda Pharmaceuticals: Global Homepage
- [H2] Expanding access to hereditary angioedema care in Vietnam
- [H2] Recent News
- [H2] Better Health, Brighter Future
- [H2] Our Areas of Focus
- [H2] Sign up for investors newsletter
- [H3] Takeda - Global
- [H3] Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- [H3] Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- [H3] U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- [H3] Takeda Reports Third-Quarter FY2025 Results – Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind – Progressing Toward Three Transformative Launches Ahead
- [H3] Join Us
- [H3] Investors
- [H3] R&D
- [H3] Gastrointestinal and Inflammation
- [H3] Rare Diseases
- [H3] Plasma-Derived Therapies
- [H3] Oncology
- [H3] Neuroscience
- [H3] Vaccines
Afbeeldingen
We vonden 6 afbeeldingen in de pagina.
Goed, de meeste of alle afbeeldingen hebben een alt tekst
Text/HTML Ratio
Ratio : 2%
De ratio van text tot HTML code is below 15 procent, dit betekent dat uw pagina waarschijnlijk meer tekst nodig heeft.
Flash
Perfect, geen Flash content gevonden in uw website.
Iframe
Perfect, er zijn geen Iframes in uw website aangetroffen.
SEO Links
Herschreven URL
Perfect. Uw links zien er vriendelijk uit!
Underscores in de URLs
Perfect! Geen underscores gevonden in uw URLs.
In-page links
We vonden een totaal van 134 links inclusie 0 link(s) naar bestanden
| Ankertekst | Type | samenstelling |
|---|---|---|
| Our Company | Intern | doFollow |
| Leadership | Intern | doFollow |
| Sustainability Approach | Intern | doFollow |
| Access to Medicines | Intern | doFollow |
| Sustainability Disclosures | Intern | doFollow |
| Ethics | Intern | doFollow |
| Transparency Disclosures | Intern | doFollow |
| Positions | Intern | doFollow |
| Corporate Giving | Intern | doFollow |
| Governance Strategy | Intern | doFollow |
| Governance Structure | Intern | doFollow |
| Charters and Reports | Intern | doFollow |
| Areas of Focus | Intern | doFollow |
| Research and Development | Intern | doFollow |
| Pipeline | Intern | doFollow |
| Our Products | Intern | doFollow |
| Manufacturing | Intern | doFollow |
| Suppliers | Intern | doFollow |
| Clinical Trials | Intern | doFollow |
| Our Stories | Intern | doFollow |
| Press Releases | Intern | doFollow |
| Statements | Intern | doFollow |
| Media Resources | Intern | doFollow |
| Overview | Intern | doFollow |
| Financial Results | Intern | doFollow |
| Investor Events | Intern | doFollow |
| Investor Contact | Intern | doFollow |
| Careers | Intern | doFollow |
| Leadership | Intern | doFollow |
| Sustainability Approach | Intern | doFollow |
| Access to Medicines | Intern | doFollow |
| Ethics | Intern | doFollow |
| Corporate Giving | Intern | doFollow |
| Governance Structure | Intern | doFollow |
| Charters and Reports | Intern | doFollow |
| Research and Development | Intern | doFollow |
| Pipeline | Intern | doFollow |
| Our Products | Intern | doFollow |
| Manufacturing | Intern | doFollow |
| Suppliers | Intern | doFollow |
| Clinical Trials | Intern | doFollow |
| Press Releases | Intern | doFollow |
| Statements | Intern | doFollow |
| Media Resources | Intern | doFollow |
| Overview | Intern | doFollow |
| Financial Results | Intern | doFollow |
| Investor Events | Intern | doFollow |
| Investor Contact | Intern | doFollow |
| English | Intern | doFollow |
| Japanese | Intern | doFollow |
| English | Intern | doFollow |
| French | Intern | doFollow |
| Arabic | Intern | doFollow |
| Spanish | Intern | doFollow |
| English | Intern | doFollow |
| German | Intern | doFollow |
| Russian | Intern | doFollow |
| English | Intern | doFollow |
| French | Intern | doFollow |
| Dutch | Intern | doFollow |
| Bosnian | Intern | doFollow |
| Portuguese | Intern | doFollow |
| Bulgarian | Intern | doFollow |
| English | Intern | doFollow |
| French | Intern | doFollow |
| Spanish | Intern | doFollow |
| Chinese | Intern | doFollow |
| Spanish | Intern | doFollow |
| Croatian | Intern | doFollow |
| Czech | Intern | doFollow |
| Danish | Intern | doFollow |
| Spanish | Intern | doFollow |
| English | Intern | doFollow |
| Arabic | Intern | doFollow |
| Estonian | Intern | doFollow |
| Finnish | Intern | doFollow |
| French | Intern | doFollow |
| German | Intern | doFollow |
| Greek | Intern | doFollow |
| English | Intern | doFollow |
| Chinese | Intern | doFollow |
| Hungarian | Intern | doFollow |
| English | Intern | doFollow |
| Indonesian | Intern | doFollow |
| English | Intern | doFollow |
| Hebrew | Intern | doFollow |
| Italian | Intern | doFollow |
| Kazakh | Intern | doFollow |
| Russian | Intern | doFollow |
| Korean | Intern | doFollow |
| Latvian | Intern | doFollow |
| Lithuanian | Intern | doFollow |
| English | Intern | doFollow |
| Spanish | Intern | doFollow |
| Dutch | Intern | doFollow |
| English | Intern | doFollow |
| Norweigan | Intern | doFollow |
| Spanish | Intern | doFollow |
| English | Intern | doFollow |
| Polish | Intern | doFollow |
| Portuguese | Intern | doFollow |
| Romanian | Intern | doFollow |
| Russian | Intern | doFollow |
| English | Intern | doFollow |
| Arabic | Intern | doFollow |
| Serbian | Intern | doFollow |
| English | Intern | doFollow |
| Slovak | Intern | doFollow |
| Slovenian | Intern | doFollow |
| English | Intern | doFollow |
| Spanish | Intern | doFollow |
| Swedish | Intern | doFollow |
| German | Intern | doFollow |
| French | Intern | doFollow |
| Chinese | Intern | doFollow |
| Thai | Intern | doFollow |
| Turkish | Intern | doFollow |
| Ukrainian | Intern | doFollow |
| English | Intern | doFollow |
| Arabic | Intern | doFollow |
| English | Intern | doFollow |
| English | Intern | doFollow |
| English | Intern | doFollow |
| - | Intern | doFollow |
| Locations | Intern | doFollow |
| Contact us | Intern | doFollow |
| Careers | Intern | doFollow |
| Financial Highlights | Intern | doFollow |
| HCPs | Intern | doFollow |
| Patients | Intern | doFollow |
| Terms and Conditions | Intern | doFollow |
| Privacy Notice | Intern | doFollow |
| Cookie Policy | Intern | doFollow |
| Accessibility Statement | Intern | doFollow |
SEO Keywords
Keywords Cloud
french corporate more takeda arabic drug diseases patients english spanish
Keywords Consistentie
| Keyword | Content | Title | Keywords | Description | Headings |
|---|---|---|---|---|---|
| english | 38 |  |
|
|
|
| spanish | 14 | |
|
|
|
| diseases | 11 | |
|
|
 |
| french | 10 | |
|
|
|
| takeda | 9 | |
|
|
|
Bruikbaarheid
Url
Domein : takeda.com
Lengte : 10
Favicon
Goed, uw website heeft een favicon.
Printbaarheid
Jammer. We vonden geen Print-Vriendelijke CSS.
Taal
Goed. Uw ingestelde taal is en.
Dublin Core
Deze pagina maakt geen gebruik van Dublin Core.
Document
Doctype
HTML 5
Encoding
Perfect. Uw ingestelde Charset is UTF-8.
W3C Validiteit
Fouten : 0
Waarschuwingen : 0
E-mail Privacy
Waarschuwing! Er is op zijn minst 1 e-mailadres gevonden als platte tekst. (voorkom spam!). Gebruik deze gratis antispam protector om e-mailadressen te verbergen voor spammers.
Niet ondersteunde HTML
Geweldig! We hebben geen niet meer ondersteunde HTMl tags gevonden in uw HTML.
Speed Tips
|
Geweldig, uw website heeft geen tabellen in een tabel. |
|
Jammer, uw website maakt gebruik van inline styles. |
|
Jammer, uw website heeft teveel CSS bestanden (meer dan 4). |
|
Jammer, uw website heeft teveel JS bestanden (meer dan 6). |
|
Perfect, uw website haalt voordeel uit gzip. |
Mobile
Mobile Optimization
|
Apple Icon |
|
Meta Viewport Tag |
|
Flash content |
Optimalisatie
XML Sitemap
Geweldig, uw website heeft een XML sitemap.
| https://www.takeda.com/sitemap.xml |
Robots.txt
https://takeda.com/robots.txt
Geweldig uw website heeft een robots.txt bestand.
Analytics
Ontbrekend
We hadden niet op te sporen van een analytics tool op deze website geplaatst.
Web Analytics laat u toe de bezoekersactiviteit op uw website te meten. U zou minstens 1 Analytics tool geïnstalleerd moeten hebben en een extra tool voor de bevestiging van de resultaten.
PageSpeed Insights
Device
Categorieën
Free SEO Testing Tool
Website review is een gratis tool waarmee u eenvoudig uw website kunt analyseren